6 December 2024 – The information letter on the triennial review for 2025 was sent to all marketing authorization holders by the Federal Office of Public Health (FOPH). As in previous years, the letter contains information on the conduct of the review and, in addition to the manual on SL, explanations on the assessment of the criteria of efficacy, appropriateness and cost-effectiveness.

In 2025, the triennial review of listing requirements will take place via the electronic platform services (ePS) application for the first time.

The information letter and the list of medicinal products that are expected to be reviewed in 2025 are available here.